Tango Therapeutics, Inc. (TNGX) stock intrinsic value fair value estimate & owner earnings analysis

Tango Therapeutics is a clinical-stage oncology company developing drugs based on synthetic lethality - targeting cancer cells that have lost a specific gene by attacking the backup pathway they now depend on. Its two clinically active programs are vopimetostat (a PRMT5 inhibitor) and TNG260 (a CoREST inhibitor); the company discontinued its most advanced program, TNG908, in November 2024 after trial data showed the drug did not reach effective concentrations in the brain, and also discontinued a second program, TNG348. Several other candidates remain in earlier, preclinical development. For years the company partnered with Gilead Sciences, which paid a total of $199 million in upfront and milestone payments starting in 2018. That money was recognized as revenue gradually, as research work was performed. In the third quarter of 2025, the research phase of the Gilead collaboration ended; the $53.8 million not yet recognized was booked as revenue all at once. Tango now has no further research obligations to Gilead, and results reported since then confirm no further collaboration revenue is coming - the business is effectively pre-revenue going forward, funding its own research from its cash. That cash position is substantial: as of the most recent quarter, the company held just over $1.0 billion in cash and short-term investments, with no debt. Against that, the business is spending roughly $220 million a year once the one-time Gilead item is excluded, funding two mid-stage clinical programs and earlier research. Because we only assign value to things that are already secured or proven - not to the hope that an early or mid-stage cancer drug eventually wins approval - our valuation gives no dollar credit to the pipeline succeeding. TNG908's failure on a basic pharmacology measure (getting enough drug into the brain) after already clearing FDA review is a reminder of how much can still go wrong even once a drug reaches the clinic. Instead, the three cases below differ only in how fast the company's cash is spent: - Bear case ($0.94/share): spending keeps growing at roughly its recent historical pace (about 10% a year) as remaining programs advance into costlier later-stage trials, exhausting the cash pile in a little over three years, after which no further value is assumed. - Base case ($1.01/share): spending holds near its current annualized level for a few years, then eases moderately - consistent with the company's demonstrated willingness to cut underperforming programs - but the cash still runs out within the ten-year window. - Bull case ($1.18/share): the company narrows its pipeline further and reduces spending meaningfully, extending its cash runway the longest of the three cases. In every case, once the cash is spent, we assume nothing further is worth counting unless a program has actually produced an approved, revenue-generating drug - none has yet. The company carries no debt, so shareholders bear no leverage risk; essentially all of today's estimated value is the cash on the balance sheet, discounted for the pace at which it is likely to be spent down. This is a deliberately conservative view. If vopimetostat, TNG260, or an earlier-stage program produces convincing clinical data, or the company signs a new partnership on favorable terms, the shares could be worth meaningfully more than shown here - but that value can't be put a number on today, so it has been left out rather than guessed at. We would revisit this case if either of those things happens. Given how much of the outcome depends on spending discipline that can only be confirmed over time, the margin-of-safety price is set at a considerable discount to even the bear-case estimate.